426 related articles for article (PubMed ID: 12640630)
41. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
[TBL] [Abstract][Full Text] [Related]
42. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
43. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
DeSimone J; Koshy M; Dorn L; Lavelle D; Bressler L; Molokie R; Talischy N
Blood; 2002 Jun; 99(11):3905-8. PubMed ID: 12010787
[TBL] [Abstract][Full Text] [Related]
44. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
Fibach E; Burke LP; Schechter AN; Noguchi CT; Rodgers GP
Blood; 1993 Mar; 81(6):1630-5. PubMed ID: 7680923
[TBL] [Abstract][Full Text] [Related]
45. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
46. Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness.
Zhu X; Hu T; Ho MH; Wang Y; Yu M; Patel N; Pi W; Choi JH; Xu H; Ganapathy V; Kutlar F; Kutlar A; Tuan D
Haematologica; 2017 Dec; 102(12):1995-2004. PubMed ID: 28971909
[TBL] [Abstract][Full Text] [Related]
47. Long-term use of hydroxyurea for sickle cell anemia.
Hagar W
JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
[No Abstract] [Full Text] [Related]
48. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients.
Conran N; Oresco-Santos C; Acosta HC; Fattori A; Saad ST; Costa FF
Br J Haematol; 2004 Feb; 124(4):547-54. PubMed ID: 14984506
[TBL] [Abstract][Full Text] [Related]
49. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate.
McDonagh KT; Dover GJ; Donahue RE; Nathan DG; Agricola B; Byrne E; Nienhuis AW
Exp Hematol; 1992 Nov; 20(10):1156-64. PubMed ID: 1385194
[TBL] [Abstract][Full Text] [Related]
50. Effects of hydroxurea, stem cell factor, and erythropoietin in combination on fetal hemoglobin in the baboon.
Lavelle D; Molokie R; Ducksworth J; DeSimone J
Exp Hematol; 2001 Feb; 29(2):156-62. PubMed ID: 11166454
[TBL] [Abstract][Full Text] [Related]
51. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Ballas SK; Connes P;
Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
[TBL] [Abstract][Full Text] [Related]
52. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
53. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
54. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
55. Hydroxyurea and sickle cell anemia: effect on quality of life.
Ballas SK; Barton FB; Waclawiw MA; Swerdlow P; Eckman JR; Pegelow CH; Koshy M; Barton BA; Bonds DR
Health Qual Life Outcomes; 2006 Aug; 4():59. PubMed ID: 16942629
[TBL] [Abstract][Full Text] [Related]
56. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
[TBL] [Abstract][Full Text] [Related]
57. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Little JA; Hauser KP; Martyr SE; Harris A; Maric I; Morris CR; Suh JH; Taylor J; Castro O; Machado R; Kato G; Gladwin MT
Eur J Haematol; 2009 Apr; 82(4):315-21. PubMed ID: 19215288
[TBL] [Abstract][Full Text] [Related]
58. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.
Ghatpande SS; Choudhary PK; Quinn CT; Goodman SR
Exp Biol Med (Maywood); 2008 Dec; 233(12):1510-7. PubMed ID: 18849548
[TBL] [Abstract][Full Text] [Related]
59. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease.
Maier-Redelsperger M; Noguchi CT; de Montalembert M; Rodgers GP; Schechter AN; Gourbil A; Blanchard D; Jais JP; Ducrocq R; Peltier JY
Blood; 1994 Nov; 84(9):3182-8. PubMed ID: 7524767
[TBL] [Abstract][Full Text] [Related]
60. Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes.
Mundee Y; Bigelow NC; Davis BH; Porter JB
Clin Lab Haematol; 2001 Jun; 23(3):149-54. PubMed ID: 11553054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
